• +1-646-491-9876
    • +91-20-67278686

    Search

    A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5-Pipeline Review H1 2017

    A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5-Pipeline Review H1 2017

    • Report Code ID: RW0001834428
    • Category Pharmaceuticals
    • No. of Pages 45
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, H1 2017

    Summary

    A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - A disintegrin and metalloproteinase with thrombospondin motifs 5 or ADAMTS5 is an enzyme encoded by the ADAMTS5 gene. It plays an important role in the destruction of aggrecan in arthritic diseases and in proteolytic processing mostly during the peri-implantation period.

    A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1 and 1 respectively. Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular and Respiratory which include indications Osteoarthritis, Allergic Asthma, Arthralgia, Arthritis, Edema and Seasonal Allergic Rhinitis.

    The latest report A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Pipeline Review, H1 2017, outlays comprehensive information on the A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.)
    - The report reviews A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects
    - The report assesses A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Overview
    A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Companies Involved in Therapeutics Development
    Asahi Kasei Pharma Corp
    Galapagos NV
    GlaxoSmithKline Plc
    Paradigm Biopharmaceuticals Ltd
    Rottapharm Biotech Srl
    A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Drug Profiles
    CRB-0017 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GLPG-1972 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-2394002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pentosan polysulfate sodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit ADAMTS-5 for Osteoarthritis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Dormant Products
    A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Product Development Milestones
    Featured News & Press Releases
    May 16, 2017: Paradigm's preclinical hay fever trial: peer-reviewed and published in leading scientific journal
    Apr 29, 2017: Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI
    Mar 23, 2017: Paradigm Biopharmaceuticals Announces Final participant treated in Phase 2 hay fever trial
    Mar 07, 2017: The Australian Company Testing a Breakthrough Treatment for Ross River
    Nov 22, 2016: Paradigm Phase 2 Hay Fever Trialgets Approval from Swedish MPA
    Sep 16, 2016: Preclinical study underpins efficacy of Paradigms Rhinosul for hay fever treatment
    Sep 07, 2016: Paradigm's PPS as a potential breakthrough in t he treatment of viral arthritis and joint pain
    Aug 19, 2016: Market update Paradigm's PPS nasal spray to treat Allergic Rhinitis (Hay Fever)
    May 25, 2016: Paradigm Biopharmaceuticals Provides Update on Rhinosul (pentosan polysulfate sodium)
    Mar 02, 2016: Paradigm initiates second clinical trial site to investigate ZILOSUL as a treatment for bone bruising following Anterior Cruciate Ligament (ACL) injury
    Feb 25, 2016: First participant in Paradigm's clinical trial starts ZILOSUL treatment for bone bruising following Anterior Cruciate Ligament (ACL) injury
    Feb 23, 2016: Paradigm starts clinical trial to investigate ZILOSUL as a treatment for bone bruising following Anterior Cruciate Ligament (ACL) injury
    Dec 03, 2015: Elite athlete from a major sporting code treated with Paradigm's ZILOSUL under the Therapeutic Goods Administration's Special Access Scheme
    Nov 23, 2015: Paradigm's ZILOSUL approved for clinical trial
    Nov 20, 2015: Galapagos initiates Phase 1 First-in-Human study with GLPG1972, receives EU3.5 million milestone from Servier
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Asahi Kasei Pharma Corp, H1 2017
    Pipeline by Galapagos NV, H1 2017
    Pipeline by GlaxoSmithKline Plc, H1 2017
    Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2017
    Pipeline by Rottapharm Biotech Srl, H1 2017
    Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Asahi Kasei Pharma Corp
    Galapagos NV
    GlaxoSmithKline Plc
    Paradigm Biopharmaceuticals Ltd
    Rottapharm Biotech Srl

    Request for Sample

    Report Url http://www.reportsweb.com//a-disintegrin-and-metalloproteinase-with-thrombospondin-motifs-5-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//a-disintegrin-and-metalloproteinase-with-thrombospondin-motifs-5-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//a-disintegrin-and-metalloproteinase-with-thrombospondin-motifs-5-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments